Sumitomo Mitsui DS Asset Management Company Ltd Purchases 911 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 15,171 shares of the biopharmaceutical company’s stock after acquiring an additional 911 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Regeneron Pharmaceuticals were worth $11,504,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Armstrong Advisory Group Inc. grew its position in Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 780.0% during the 3rd quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 39 shares in the last quarter. Finally, Alpine Bank Wealth Management bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $34,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $807.48 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a market cap of $83.14 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The stock’s fifty day simple moving average is $791.41 and its two-hundred day simple moving average is $721.87. Regeneron Pharmaceuticals, Inc. has a 1-year low of $572.75 and a 1-year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.98 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a report on Thursday, October 1st. Finally, Robert W. Baird raised their price target on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $845.59.

Insider Activity

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.